Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago.
MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates
MacroGenics (MGNX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of a loss of $0.48 per share. This compares to earnings of $0.9 per share a year ago.
MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for MacroGenics (MGNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago.
MacroGenics: Working On That Road To Recovery
I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with key phase 2 data expected in late 2025, and additional programs like MGC-026 and MGC-028 progressing. The recent royalty deal extends the cash runway, but liquidity concerns remain, and further asset sales or dilution may be necessary.
